益心舒胶囊对急性脑梗死患者PAC-1和IL-18表达的影响

Effect of Yixinshu capsules on PAC-1 and IL-18 expression in patients with acute cerebral infarction

目的探讨益心舒胶囊对急性脑梗死患者血小板膜糖蛋白Ⅱb/Ⅲa纤维蛋白原受体-1(PAC-1)和白介素-18(IL-18)表达的影响。方法选择2012年6月至2015年2月期间在我院诊治的110例急性脑梗死患者,采用随机平行对照的方法分为治疗组与对照组各55例,所有患者均给予脑血管病常规治疗,在此基础上治疗组加用益心舒胶囊治疗,疗程2周。结果治疗后治疗组与对照组的治疗总有效率分别为96.4%和80.0%,组间比较差异有统计学意义(P<0.05)。治疗后治疗组与对照组的PAC-1含量分别为(3.45±1.31)μg/m L和(4.92±2.13)μg/m L,均明显低于治疗前的(9.34±1.87)μg/m L和(9.29±2.10)μg/m L(P<0.05),组间比较差异有统计学意义(P<0.05)。治疗后治疗组与对照组的IL-18含量分别为(40.45±1.67)pg/m L和(45.45±2.92)pg/m L,均明显低于治疗前的(56.45±1.45)pg/m L和(56.32±3.93)pg/m L(P<0.05),组间比较差异有统计学意义(P<0.05)。治疗后随访3个月,治疗组的短暂性脑缺血、靶血管血运重建、出血性梗死、心力衰竭等主要不良心脑血管事件发生情况明显少于对照组(P<0.05)。结论益心舒胶囊辅助治疗急性脑梗死可以抑制PAC-1和IL-18的表达,提高治疗疗效,并且能降低随访主要不良心脑血管事件的发生,值得推广应用。

Objective To investigate the effect of Yixinshu capsules on expression of platelet membrane glycoprotein Ⅱb / Ⅲa fibrinogen receptor-1（ PAC-1） and interleukin-18（ IL-18） in patients with acute cerebral infarction. Methods Totally 110 patients with acute cerebral infarction in our hospital from June 2012 to February 2015 were selected,and divided into treatment group and control group according to randomized parallel control methods,55 patients in each group. All patients were given conventional cerebrovascular disease treatment,and treatment group was added with Yixinshu capsule on the basis of control group,all treatment lasting for 2 weeks. Results After treatment,the total effective rates of treatment group and control group were 96. 4% and 80. 0% respectively,and there was significant difference between the two groups（ P〈0. 05）. The PAC-1 contents of treatment group and control group were（ 3. 45 ± 1. 31） μg /m L and（ 4. 92 ± 2. 13） μg /m L after treatment,which were significantly lower than before treatment [（ 9. 34 ± 1. 87） μg / m L and（ 9. 29 ± 2. 10） μg / m L]（ P〈0. 05）,and there were significant differences between the two groups（ P〈0. 05）. The IL-18 contents in treatment group and control group were（ 40. 45 ± 1. 67） pg / m L and（ 45. 45 ± 2. 92） pg /m L after treatment,which were significantly lower than before treatment [（ 56. 45 ± 1. 45） pg /m L and（ 56. 32 ± 3. 93） pg / m L],and there were significant differences between the two groups（ P〈0. 05）. During the followed-up of three months after treatment,the incidences of transient cerebral ischemia,target vessel revascularization,hemorrhagic infarction,heart failure and other major adverse cardiac and cerebrovascular events in treatment group were significantly less than in control group（ P〈0. 05）. Conclusion Yixinshu capsule treatment for acute cerebral infarction can inhibit the PAC-1 and IL-18 expression and improve the therapeutic effect,which can reduce the incidence of major adverse cardiac and cerebrovascular event and is worthy of being widely applied.